Bimagrumab Phase 2 trial (NCT03005288)
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 78
- actual
- Start
- 1 Feb 2017 (actual)
- Primary completion
- 21 Mar 2019 (actual)
- Sponsor
- Novartis Pharmaceuticals
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| BYM338 10 mg/kg | Experimental | Drug: BYM338 10 mg/kg | Bimagrumab (BYM338) 10 mg/kg up to maximum 1200 mg, every 4 weeks until week 44 (12 doses) |
| Placebo | Placebo comparator | Other: Placebo | Placebo, every 4 weeks until week 44 (12 doses) |
Primary endpoint
| Measure | Time frame |
|---|---|
| Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 48 | Baseline, Week 48 |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 24 | Baseline, Week 24 |
| Change From Baseline in HbA1c at Week 24 and 48 | Baseline, Week 24, Week 48 |
| The Trough Observed Analyte Concentration (Ctrough) of Repeat Doses of BYM338 10 mg/kg on Day 84, 168, 252, 308 and 336 | Day 84, 252, 336 at pre-dose only. Day 168, 308 at pre-dose and 45 mins post-dose |
| Maximum Observed Serum Concentration(Cmax) Derived on Day 1, 168 and 308 | Day 1, 168, 308 at pre-dose and 45 mins post-dose |
| Time to Reach the Maximum Concentration After Drug Administration (Tmax) Derived on Day 168 and 308 | Day 1, 168, 308 at pre-dose and 45 mins post-dose |
| Change From Baseline in Body Mass Index (BMI) | Baseline, Week 24, Week 48 |
| Change From Baseline in Weight | Baseline, Week 24, Week 48 |
| Change From Baseline in Lean Body Mass (LBM) Measured by DXA | Baseline, Week 24, Week 48 |
| Change From Baseline in Waist Circumference | Baseline, Week 24, Week 52 |
| Change From Baseline in Waist to Hip Ratio | Baseline, Week 24, Week 52 |
| Change From Baseline in Insulin Resistance (HOMA2-IR) | Baseline. Week 12, Week 36 |
| Immunogenicity Assessed by the Number of Participants Developing Anti-BYM338 Antibodies During the Trial | 392 days |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Results
Results are posted on the registry. Open the ClinicalTrials.gov record for NCT03005288.
What the registry posted for the bimagrumab fat-mass outcome
The posted primary outcome is the change from baseline in total body fat mass by DXA at week 48.[1]
Outcome group OG000 is labelled BYM338 10 mg/kg, which is the code name for bimagrumab.[1]
The posted least-squares mean change in fat mass was -7.49 kg in the first group, with bounds of -8.33 to -6.64, and -0.18 kg in the second, with bounds of -0.99 to 0.63.[1]
The posted net mean difference was -7.31, with an 80% two-sided interval of -8.48 to -6.14.[1]
Sources
- 1A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.